Alembic Pharmaceuticals Receives USFDA Tentative Approval for Alogliptin Tablets

Pharma Major Alembic Pharmaceuticals Limited said that company has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Alogliptin Tablets, 6.25 mg, 12.5 mg, and 25mg. The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), NESINA Tablets, 6.25 mg, 12. – United News of India